$10.56 Million in Sales Expected for Cellectis S.A. (CLLS) This Quarter
Equities research analysts forecast that Cellectis S.A. (NASDAQ:CLLS) will post sales of $10.56 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cellectis’ earnings. The lowest sales estimate is $10.00 million and the highest is $11.12 million. Cellectis posted sales of $12.62 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 16.3%. The company is expected to issue its next quarterly earnings results on Tuesday, November 28th.
On average, analysts expect that Cellectis will report full-year sales of $10.56 million for the current year, with estimates ranging from $39.70 million to $44.00 million. For the next fiscal year, analysts anticipate that the business will report sales of $40.15 million per share, with estimates ranging from $36.00 million to $44.46 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Cellectis.
A number of research analysts have weighed in on CLLS shares. BidaskClub raised shares of Cellectis from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 23rd. Jefferies Group LLC set a $47.00 price target on shares of Cellectis and gave the company a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research raised shares of Cellectis from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a research note on Wednesday, July 19th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $40.00 price target (up previously from $33.00) on shares of Cellectis in a research note on Tuesday, September 5th. Finally, Nomura cut their price target on shares of Cellectis from $49.00 to $43.00 and set a “buy” rating on the stock in a research note on Wednesday, September 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $39.00.
TRADEMARK VIOLATION NOTICE: This piece was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/15/10-56-million-in-sales-expected-for-cellectis-s-a-clls-this-quarter.html.
Cellectis (NASDAQ:CLLS) opened at 28.42 on Friday. The firm’s market cap is $1.02 billion. Cellectis has a 1-year low of $16.09 and a 1-year high of $29.00. The firm has a 50-day moving average of $27.53 and a 200 day moving average of $24.52.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sphera Funds Management LTD. increased its holdings in Cellectis by 27.6% during the second quarter. Sphera Funds Management LTD. now owns 203,764 shares of the biotechnology company’s stock worth $5,261,000 after buying an additional 44,100 shares during the last quarter. Vident Investment Advisory LLC increased its holdings in Cellectis by 20.0% during the first quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock worth $1,224,000 after buying an additional 8,496 shares during the last quarter. Balyasny Asset Management LLC acquired a new position in Cellectis during the second quarter worth $719,000. Eqis Capital Management Inc. increased its holdings in Cellectis by 27.2% during the second quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock worth $276,000 after buying an additional 2,287 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Cellectis by 132.1% during the second quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after buying an additional 5,435 shares during the last quarter. Institutional investors and hedge funds own 14.85% of the company’s stock.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.